Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dan M Roden

Showing results (31-40 of 593) with videos related to

Pageof 60
Sort By:
Heart Rhythm|February 5, 2010
Brugada syndrome: lots of questions, some answersDan M Roden
Circulation|September 4, 2008
Repolarization reserve: a moving targetDan M Roden
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|April 9, 2011
Personalized medicine and the genotype-phenotype dilemmaDan M Roden
The New England Journal of Medicine|January 11, 2008
Clinical practice. Long-QT syndromeDan M Roden
Cardiac Electrophysiology Clinics|November 15, 2014
Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugsDan M Roden
Heart Rhythm|April 21, 2005
Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillationDawood Darbar, Dan M Roden
Current Opinion in Cardiology|June 7, 2006
Future of antiarrhythmic drugsDawood Darbar, Dan M Roden
Current Cardiology Reports|May 22, 2013
Pharmacogenomics and cardiovascular diseasePeter Weeke, Dan M Roden
Circulation|April 7, 2005
The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval processDan M Roden, Robert Temple
Expert Opinion on Pharmacotherapy|July 29, 2006
Pharmacogenetics of antiarrhythmic therapyDawood Darbar, Dan M Roden
Pageof 60

Showing results (31-40 of 593) with videos related to

Sort By:
Pageof 60
Heart Rhythm|February 5, 2010
Brugada syndrome: lots of questions, some answersDan M Roden
Circulation|September 4, 2008
Repolarization reserve: a moving targetDan M Roden
Journal of Interventional Cardiac Electrophysiology : an International Journal of Arrhythmias and Pacing|April 9, 2011
Personalized medicine and the genotype-phenotype dilemmaDan M Roden
The New England Journal of Medicine|January 11, 2008
Clinical practice. Long-QT syndromeDan M Roden
Cardiac Electrophysiology Clinics|November 15, 2014
Pharmacology and Toxicology of Nav1.5-Class 1 anti-arrhythmic drugsDan M Roden
Heart Rhythm|April 21, 2005
Symptomatic burden as an endpoint to evaluate interventions in patients with atrial fibrillationDawood Darbar, Dan M Roden
Current Opinion in Cardiology|June 7, 2006
Future of antiarrhythmic drugsDawood Darbar, Dan M Roden
Current Cardiology Reports|May 22, 2013
Pharmacogenomics and cardiovascular diseasePeter Weeke, Dan M Roden
Circulation|April 7, 2005
The US Food and Drug Administration Cardiorenal Advisory Panel and the drug approval processDan M Roden, Robert Temple
Expert Opinion on Pharmacotherapy|July 29, 2006
Pharmacogenetics of antiarrhythmic therapyDawood Darbar, Dan M Roden
Pageof 60